Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
DEFLAZACORT
Shire Pharmaceuticals Limited
DEFLAZACORT
1mg Milligram
Tablets
Withdrawn
2007-10-31
IRISH MEDICINES BOARD ACT 1995 MEDICINAL PRODUCTS(LICENSING AND SALE)REGULATIONS, 1998 (S.I. NO.142 OF 1998) PA0535/005/001 Case No: 2035807 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to SHIRE PHARMACEUTICALS LIMITED HAMPSHIRE INTERNATIONAL BUSINESS, CHINEHAM, BASINGSTOKE, HAMPSHIRE RG24 8EP, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product CALCORT 1MG TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 08/05/2007 until 14/06/2009. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 15/05/2007_ _CRN 2035807_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Calcort 1 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains Deflazacort 1mg. For excipients, see 6.1 3 PHARMACEUTICAL FORM Tablet Round white tablet, plain on one face and marked with a ‘1’ on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS A wide range of conditions may sometimes need treatment with glucocorticoids. The indications include: Primary and secondary adrenocortical insufficiency, rheumatological disorders, collagen diseases, pulmonary diseases, allergic conditions, haematological diseases, neoplastic diseases, dermatological diseases, renal diseases, Citiți documentul complet